statistiche ricercatore

COSCIA, MARTA

Distribuzione geografica

Continente	#
NA - Nord America	833
EU - Europa	372
AS - Asia	243
AF - Africa	1
Totale	1.449

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	825
SG - Singapore	213
IT - Italia	198
RU - Federazione Russa	107
CN - Cina	28
DE - Germania	14
IE - Irlanda	13
NL - Olanda	12
CA - Canada	8
GB - Regno Unito	8
FI - Finlandia	6
LT - Lituania	5
SE - Svezia	4
UA - Ucraina	4
VN - Vietnam	2
CZ - Repubblica Ceca	1
ZA - Sudafrica	1
Totale	1.449

Salva come PNG Salva come JPEG

Città	#
Boardman	236
Singapore	209
Chicago	205
Santa Clara	45
Assago	26
Milan	18
Dublin	13
Munich	11
Vergiate	9
Ashburn	8
Chandler	8
Fairfield	6
Moscow	6
Romola	6
Guidonia Montecelio	5
Helsinki	5
Amsterdam	4
Houston	4
London	4
Ottawa	4
Rome	4
Toronto	4
Fort Worth	3
Jacksonville	3
Nyköping	3
Seattle	3
Varese	3
Wilmington	3
Acerra	2
Ann Arbor	2
Bologna	2
Frankfurt am Main	2
Princeton	2
Rende	2
Woodbridge	2
Brno	1
Buffalo	1
Cambridge	1
Cosenza	1
Dong Ket	1
Fayetteville	1
Prineville	1
Redwood City	1
San Diego	1
Totale	881

Salva come PNG Salva come JPEG

Nome	#
AISF position paper on HCV in immunocompromised patients	95
Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study	23
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study	18
BTK and PLCG2 mutations in patients with Chronic Lymphocytic Leukemia relapsing on Ibrutinib: a European Research Initiative on CLL (ERIC) study based on real-world evidence	12
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN CLL PATIENTS	11
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL)	11
Longitudinal Assessment of CLL Patients Under Ibrutinib Treatment Reveals Maintained Capacity to Respond to Microenvironmental Stimuli through the Toll-like Receptors	11
NEW PROSPECTS FOR INDUCTION OF ANTI-LYMPHOMA IMMUNITY USING DNA VACCINES EXPRESSING CHEMOKINE-PARTICLES	11
Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges	11
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells	11
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	11
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	11
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS	10
B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide	10
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus	10
Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells	10
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape	10
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino	10
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target	10
Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene	10
Myeloma cells drive the maturation of dendritic cells versus a Th2-promoting phenotype which impairs T-cell activation	10
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study	9
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs	9
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells	9
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation	9
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 - 'Veritas' study	9
Frequency and function of regulatory T cells (Tregs) are highly preserved in multiple myeloma	9
LDH Levels Predict Progression-Free Survival in Treatment-NaIVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia	9
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives	9
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy	9
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status	9
ROLE OF THE MEVALONATE PATHWAY IN THE IMMUNOMODULATORY ACTIVITY OF ZOLEDRONIC ACID	9
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	9
Continuous venetoclax in treatment‐naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study	9
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide	9
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)	9
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study	9
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA	9
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia	9
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells	9
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study	8
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: Multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials	8
Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients	8
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials	8
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome	8
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells	8
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia	8
Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia	8
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice	8
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs	8
BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib	8
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia	8
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia	8
Therapeutic idiotype vaccines in B lymphoproliferative diseases	8
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	8
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment	8
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia	8
Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights	8
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia	8
Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma	8
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study	8
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway	8
LDH as Predictive Parameter in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12	8
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment	8
Immunoglobulin variable heavy-chain (Ig Vh) mutational status and tumor microenvironment interactions in B-cell chronic lymphocytic leukaemia	8
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS	8
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells	8
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience	8
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma	8
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia	8
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	8
Expression of the Tigit/CD226/CD155 Receptors/Ligand System in Chronic Lymphocytic Leukemia	7
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells	7
Regulation Of CLL Growth and Trafficking By The Enzymatic Functions Of CD38: Implications For Therapeutic Targeting	7
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response	7
The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia	7
Mutations in NOTCH1 PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia cells by modulating the tumor suppressor gene DUSP22	7
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE	7
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia	7
Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method	7
Effective anti-tumor immunomodulatory properties of zoledronic acid	7
Magic pills: new oral drugs to treat chronic lymphocytic leukemia	7
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL	7
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY	7
CD73-generated extracellular adenosine creates microenvironmental conditions favoring growth and survival of chronic lymphocytic leukemia cells	7
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study	7
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications	7
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab	7
Extracellular Nicotinamide Phosphoribosyltransferase (NAMPT) Shapes the CLL Microenvironment Promoting Macrophage M2 Polarization Via a Non-Enzymatic Mechanism	7
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group	7
Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib	7
Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells	7
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS	7
CD200 INCLUDED IN A 4-MARKER MODIFIED MATUTES SCORE PROVIDES OPTIMAL SENSITIVITYAND SPECIFICITY FOR THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA	7
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia	7
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PRELIMINARY REPORT OF THE ITALIAN TRIAL	7
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance	7
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy	7
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia	7
ROLE OF THE MEVALONATE PATHWAY IN THE IMMUNOMODULATORY ACTIVITY OF ZOLEDRONIC ACID	7
Totale	948

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	14.792
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	14.792

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	33	4	1	9	1	3	2	0	4	2	2	1	4
2021/2022	7	0	0	2	0	0	0	0	1	1	1	1	1
2022/2023	23	2	1	3	1	3	3	0	3	5	0	0	2
2023/2024	27	4	5	5	5	6	0	0	1	0	0	0	1
2024/2025	1.595	239	34	868	158	181	115	0	0	0	0	0	0
Totale													1.685